IOVA Company Profile and Key Details
Iovance Biotherapeutics, Inc.
IOVA Stock Price Chart
Stock Price Today
Iovance Biotherapeutics, Inc. (IOVA) stock surged +2.32%, trading at $5.95 on NASDAQ, up from the previous close of $5.81. The stock opened at $5.84, fluctuating between $5.84 and $6.02 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Company Information
| Employees | 557 |
| Beta | 0.59 |
| Sales or Revenue | $1.19M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) stock price is $5.95 in the last trading session. During the trading session, IOVA stock reached the peak price of $6.02 while $5.84 was the lowest point it dropped to. The percentage change in IOVA stock occurred in the recent session was 2.32% while the dollar amount for the price change in IOVA stock was $0.14.
The NASDAQ listed IOVA is part of Biotechnology industry that operates in the broader Healthcare sector. Iovance Biotherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Sara Pellegrino
Vice President of Investor Relations & PR
Mr. Jean-Marc Bellemin M.B.A.
Chief Financial Officer, Principal Accounting Officer & Treasurer
Dr. Raj K. Puri M.D., Ph.D.
Executive Vice President of Regulatory Strategy & Translational Medicine
Ms. Tracy Winton
Senior Vice President of HR
Mr. Madan Jagasia
Executive Vice President of Medical Affairs
Dr. Igor P. Bilinsky
Chief Operating Officer
Mr. Brian Shew M.B.A.
Senior Vice President & Head of Digital and Information Technology
Mr. Howard B. Johnson M.B.A.
Chief Bus. Officer
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Interim Chief Executive Officer, Pres, Gen. Counsel & Corporation Sec.
Mr. James Ziegler M.B.A.
Executive Vice President of Commercial
Dr. Friedrich Graf Finckenstein M.D.
Chief Medical Officer
IOVA's closing price is 5.25% higher than its 52-week low of $5.52 where as its distance from 52-week high of $18.33 is -68.3%.
Number of IOVA employees currently stands at 557.
Official Website of IOVA is: https://www.iovance.com
IOVA could be contacted at phone 650 260 7120 and can also be accessed through its website. IOVA operates from 825 Industrial Road, San Carlos, CA 94070, United States.
IOVA stock volume for the day was 2.21M shares. The average number of IOVA shares traded daily for last 3 months was 8.24M.
The market value of IOVA currently stands at $1.81B with its latest stock price at $5.95 and 304.78M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com